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Abstract 
 
Renal cell carcinoma (RCC) is the one of the most common type of of cancer of the kidneys  affecting adults. A 35- 
year-old man, with Von Hippel Lindau (VHL) syndrome was referred for bilateral renal mass in a follow up CT for 
evaluation. Open partial left nephrectomy was performed and the final histopathological report confirmed the 
diagnosis. One of the most important genetic and hereditary risk factor for RCC is Von Hippel-Lindau syndrome 
(VHL).  RCC in VHL may occur bilaterally in some cases, so preserving renal parenchymal function is a major 
therapeutic goal and nephron sparing surgery provides a favorable patient outcome. 
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Introduction 
 
RCC (Grawitz' tumour)  is the most common type of 
cancer of the kidneys, contributing to 90-95% cases of 
kidney cancers. RCC is seen in 3% of total cancer cases 
in adults and usually occurs in people aged more than 
55 years (mean age is 64 years)  (1). One of the most 
important genetic and hereditary risk factor for RCC is 
Von Hippel-Lindau syndrome (VHL) whereby the risk 
is estimated to be 40% and manifestations become 
apparent in a younger age group (2). With the advent of 
improved detection techniques (CT, US , and MRI) the 
incidence of RCC seems to be on the rise (3). 
Historically, TN was done to prevent or reduce the risk 
of disease progression which led to patient being 
dependent on dialysis. Since, RCC has a low 
pathological grade, slow growth and metastatis, the 
treatment is aimed at conserving renal parenchymal 
function. Hence presently, nephron sparing surgery 
(NSS) has become the gold standard of treatment 
compared to radical nephrectomy (RN) (2). 
 
 
Case Report 
 
A 35-year-old Malay man with VHL syndrome who had 
cereberal haemangioblastoma, was referred for incidental 
findings of bilateral renal mass suggestive of RCC in a 
follow up CT scan. The scan showed solid mass in the 
lower pole of right and left kidneys, measuring 1.6 cm and 
4.6 cm, respectively. He also had multiple renal cysts 
bilaterally and also pancreatic cysts. He was asymptomatic 
and had normal renal function. An extra-peritoneal 
approach open partial left nephrectomy was done and the 
histopathological report revealed clear cell RCC (Fuhrman 
nuclear grade 2). However,  a tumour free resected margin 
was not obtained. He was being followed-up with regular 
CT scans with a plan of partial nephrectomy of the 
contralateral kidney later once he recovered well. 
 
Discussion 
 
RCC usually presents above the age of 55 years. 
Hematuria, abdominal pain, and a palpable abdominal  
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mass are classic symptoms of RCC. But this triad of 
symptoms is seen only in 10% patients. Upto a quarter 
of the cases show metastatsis at presentation. Half of 
diagnosed RCC cases develop metastasis or local 
recurrence after treatment for the primary tumour 
during follow up visit. One fifth of the cases show 
common paraneoplastic syndromes like hypercalcemia, 
liver dysfunction, polycythemia, amyloidosis, fever and 
weight loss (3). 
 
Incidental detection by employing CT scan, US, and 
MRI have been steadily increasing over the years due to 
advancement in detection techniques. More than half of 
RCC cases can be identified incidentally by imaging 
techniques. The use of CT scan in the diagnosis of RCC 
increases accuracy to 95%. The tumours detected by CT 
scan are usually smaller, picked up in the earlier stages, 
and with improved survival for which partial 
nephrectomy can be carried out instead of radical 
nephrectomy (4). 
 
The above patient has RCC, despite falling into a 
younger age group and being asymptomatic (does not 
show the classic symptoms of the triad). This can be 
explained due to a strong correlation of RCC with VHL 
syndrome.  
 
Von Hippel Lindau (VHL) syndrome is a rare 
autosomal dominant genetic condition resulting from a 
mutation in the VHL tumour suppressor gene on 
chromosome 3p25.3. This disease is characterised by 
occurrence of cancers of central nervous system, retinal 
hemangioblastomas, pheochromocytomas, pancreatic 
neurondocrine tumours, pancreatic cysts, endolymphatic 
sac tumours, epididymal papillary cystadenomas, clear 
cell RCC and presents with an increased risk of 
malignant transformation (5). 
 
Nephron sparing surgery in the form of partial 
nephrectomy is the gold standard of treatment whenever 
feasible for enhancing solid renal masses (6) 
considering the fact that there is bilateral involvement in 
2-4 % of cases. In approximately one half cases with 
bilateral tumours, there is synchronous involvement 
with the risk of RCC occurring in the original 
contralateral kidney at a later point in the patient 
ranging from 1-2% . In our patient, NSS was considered 
since there were bilateral tumours. NSS can also be 
considered in patients whose renal function is of clinical 
concern especially in patients with a sole functioning 
kidney or patients with renal dysfunction. In these 
subset of patients, if the entire kidney were to be 
removed then these patients would be dependent on 
dialysis for their entire lifespan. 
 
Patients aged 40-44 years undergoing dialysis, the 
average survival rate is 8 years. Patients aged 60-64 
years the average survival rate being 4.5 years and this 
decrease in survival rate is mostly due to cardiovascular 
compromise (7).  This consideration is most obvious in 
younger patients and those with hereditary history (2).  
 
Various retrospective studies comparing PN and RN 
showed no difference in cancer specific survival and 
rate to distant metastasis at long-term followup. But 
there was greater renal function preservation with PN 
(8) along with a lower risk of recurrence rates. Earlier 
there was some concern over local recurrence and the 
need for a wider resection margin with PN.  But it was 
found that local recurrence rates with PN was rare and 
occurred only in the presence of grossly positive 
surgical margins and these concerns were no longer 
found to be valid (8). Hence, PN was found to provide 
equivalent oncological outcomes to RN for renal 
tumours < 4cm (T1a) and tumours < 7cm (T1b) (9). 
 
Another advantage of PN is the significant reduction in 
risk of inducing chronic renal failure when NSS was 
performed (9). Studies comparing radical and partial 
nephrectomy, have demonstrated a significantly reduced 
risk of chronic renal insufficiency using nephron-
sparing surgery (10). In the event of recurrence, and 
patient needing systemic drug treatment, a satisfactory 
renal function is essential and here the PN may be 
favoured over RN (10).  
 
RCC in VHL where the tumours are small can be 
monitored by imaging and for tumours ranging in size 
from 2.5-3cm, NSS in the form of partial nephrectomy 
can be performed (11). 
 
PN is generally performed with regional ischemia to 
allow tumor resection to be performed in a nearly 
bloodless field. Several techniques have been described 
for tumor resection with limited ischemic duration or 
without ischemia. Nevertheless, for more complex 
situations regional ischemia is required and may exceed 
the 30-min limit that has commonly been considered the 
safe duration for warm ischemia. Ischemia intervals of 
less than 20 mins have been associated with improved 
outcomes for OPN performed in functionally solitary 
kidneys. There is a slight decrease in the expected nadir 
GFR when the warm ischemia is more than 20-25 mins. 
However, further prolonging the ischemic time can 
decrease the renal function by the minute.  Early 
unclamping significantly decreases ischemia time by 
more than 50% with a trend toward decreased post-
operative complications (12). 
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The risk of local tumour recurrence is one of the major 
disadvantage following NSS. For smaller sized tumours 
(3-4 cm in diameter), the local recurrence is found to be 
lower. It has been reported to have an incidence of 4-
6% mostly and some even as high as 16% (11). The 
possible reasons for tumour recurrence are incomplete 
surgical margin, multifocal preexisting tumours, tumour 
spillage, and new tumour growth. RN has a major 
advantage in this issue as local recurrence rate is 
uncommon for localised RCC (9).  
 
Microscopic PSMs on final pathology can be managed 
expectantly without immediate additional treatment or 
compromised long term outcome. 5-year freedom from 
local recurrence for patients with negative margins is 
97% and for those with positive margins 98%. A 10-
year probability of freedom from metastatic progression 
is 93% for patients with negative margins and 95% for 
those with positive margins. PSMs should not be used 
as a measure of oncological outcome and moreover they 
have not been found to increase the long-term risk of 
local recurrence nor metastasis. Patients with positive 
surgical margins can be safely monitored and will not 
have any bearing on the long-term disease-free survival 
(13). Though NSS might show improved outcomes in 
good hands, there may be some surgical morbidities like 
increase incidence of urine leakage, postoperative 
bleeding, obstruction of pelviureteric junction (8) which 
can be minimised by performing laparoscopic partial 
nephrectomy (14), but for which no difference was 
observed in the oncological outcomes. 
 
Conclusion 
 
With the advent of improved imaging techniques, the 
diagnosis of RCC in VHL in early stages can be made 
much before the actual onset of metastasis. Hence, NSS 
in bilateral involvement is gold standard of treatment of 
small RCC to preserve renal function. 
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